Aisling Capital Management LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001766721
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2024 · 16 positions · Total reported value $261.07M · Top-10 concentration 97.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 21.4% · 0 new · 3 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -15.8% · vs SPY -17.9% · Prev Value $471.62M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +2.4% · vs SPY +0.3% · Latest Value $299.32M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2024 13F filing, Aisling Capital Management LP disclosed 16 equity positions with a combined reported value of $261.07M. The filing implies a focused portfolio: its ten largest positions account for 97.3% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2024 were BBIO ($154.49M), VRNA ($32.09M), SNDX ($19.73M). By sector, the heaviest allocations are Health Care 85.3%, Other 14.7%. Versus the prior quarter, allocation shifted toward Other (+2.4pp) and away from Health Care (-2.4pp).
Versus the prior quarter, Aisling Capital Management LP opened 0 new positions, trimmed 3 and fully exited 0, a turnover rate of 21.4% of positions. The portfolio's overlap with the prior quarter was 94% of names.
The largest new positions opened in Q3 2024 were BCAX ($14.49M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2024)
- BCAX BICARA THERAPEUTICS INC · $14.49M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest Aisling Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Aisling Capital Management LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 14 US equity positions with a combined value of $471.62M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-106625 (status: Approved), registered 2015-09-21
- Regulatory AUM (Form ADV): $716.44M as of 2026-03-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds
- Website: aislingcapital.com
Portfolio Structure
- 14 positions · $471.62M reported value (Q2 2026)
- Top 10 holdings = 99.0% of reported value
- Largest position: BBIO (BRIDGEBIO PHARMA INC COM) at 72.5%
- Average position size: $33.69M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 new, 1 reduced
- 12 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
6.07M | $154.49M | 59.18% | Hold | |
| 2 |
|
1.12M | $32.09M | 12.29% | Hold | |
| 3 |
|
1.02M | $19.73M | 7.56% | Hold | |
| 4 |
|
568.92K | $14.49M | 5.55% | New | |
| 5 |
|
798.76K | $8.07M | 3.09% | Hold | |
| 6 |
|
1.47M | $7.80M | 2.99% | Hold | |
| 7 |
|
964.50K | $6.08M | 2.33% | Hold | |
| 8 |
|
2.54M | $5.82M | 2.23% | Hold | |
| 9 |
|
1.04M | $2.98M | 1.14% | Hold | |
| 10 |
|
84.15K | $2.55M | 0.98% | Hold | |
| 11 |
|
521.11K | $2.31M | 0.88% | Hold | |
| 12 |
|
2.83M | $1.70M | 0.65% | Hold | |
| 13 |
|
886.08K | $1.51M | 0.58% | Hold | |
| 14 |
|
314.29K | $886.29K | 0.34% | Hold | |
| 15 |
|
434.45K | $499.62K | 0.19% | Hold | |
| 16 |
|
288.57K | $66.37K | 0.03% | Hold | |
FAQ
What did Aisling Capital Management LP buy in 2024-Q3?
In its 2024-Q3 13F filing, Aisling Capital Management LP reported 16 equity positions worth $261.07M in aggregate; its largest disclosed positions were BBIO ($154.49M), VRNA ($32.09M), SNDX ($19.73M).
How large is Aisling Capital Management LP's portfolio?
Aisling Capital Management LP reported $261.07M of long equity holdings across 16 positions as of 2024-Q3. Top-10 holdings account for 97.3% of reported value.
What is Aisling Capital Management LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.